Get the Stockscreener App
43.75
2.27%
0.97
After Hours:
43.75
Supernus Pharmaceuticals Inc stock is traded at $43.75, with a volume of 667.58K.
It is up +2.27% in the last 24 hours and down -4.58% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
See More
Previous Close:
$42.78
Open:
$43.04
24h Volume:
667.58K
Relative Volume:
0.81
Market Cap:
$2.54B
Revenue:
$776.83M
Net Income/Loss:
$-29.02M
P/E Ratio:
-85.45
EPS:
-0.512
Net Cash Flow:
$82.25M
1W Performance:
+5.98%
1M Performance:
-4.58%
6M Performance:
-8.40%
1Y Performance:
-6.88%
1-Day Range:
$42.82
$44.25
1-Week Range:
$40.75
$44.25
52-Week Range:
$40.51
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
43.75 | 2.42B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
18.95 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.52 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.25 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
497.59 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan
Supernus at Wells Fargo conference: growth after patent losses By Investing.com - Investing.com Canada
Supernus at Wells Fargo conference: growth after patent losses - Investing.com
Indivior stock gains as Supernus merger and special dividend plan come into focus - ad-hoc-news.de
Supernus at cantor global healthcare conference: merger and growth push By Investing.com - Investing.com Nigeria
Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan
SUPN: Strong CNS portfolio growth and a strategic merger position the company for accelerated innovation - TradingView
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD By Investing.com - Investing.com Canada
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD - investing.com
Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de
SUPN Stock Price, Quote & Chart - ChartMill
Supernus Pharmaceuticals Inc. (SUPN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Supernus Pharmaceuticals to Participate in September Investor Conferences - Yahoo Finance
Supernus management will appear at two September conferences in New York and Massachusetts - Stock Titan
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD - Yahoo Finance
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - barchart.com
Supernus Pharmaceuticals Inc. (SUPN) Peer Comparison – Compare with Others - Value Research
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Super - The National Law Review
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock? - TradingView
A Look at Supernus Pharmaceuticals Inc (SUPN) After 3.4% Decline -- GF Value $43.78 vs Price $45.85 - GuruFocus
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com
25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc. - MarketBeat
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - ad-hoc-news.de
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - Sahm
Britannia, US WorldMeds, Supernus must face US Apokyn antitrust case, plaintiffs say - MLex
Supernus (SUPN) Results Review: The Available Earnings Metric Delivers a Beat in the Latest Reading; After Results: Shares Move 0.35% Lower in the Current UpdateGuidance Revision Trend - vinanet.vn
Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN) - TradingView
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Sahm
Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE - MarketBeat
Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals - Kalkine Media
Supernus Pharmaceuticals CMO Jonathan Rubin Reports Vesting of 750 PSUs and Share Withholding for Taxes - Kalkine Media
Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP converts 1,650 PSUs; 797 shares withheld for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) exec converts 2,500 PSUs, withholds shares for tax - Stock Titan
Supernus Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SUPN | US8684591089 - marketscreener.com
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Why (SUPN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo Finance
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News - Yahoo Finance
Supernus Pharmaceuticals Inc. (S49.SG) Q2 FY2025 earnings call transcript - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Arrowstreet Capital Limited Partnership Trims Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rubin Jonathan | SVP, Chief Medical Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
750 |
0 |
14,342 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Aug 12 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
19,795 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
1,650 |
0 |
20,341 |
| DEC TIMOTHY C | Senior Vice-President & CFO |
Aug 12 '26 |
Option Exercise |
0.00 |
1,250 |
0 |
9,733 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Option Exercise |
38.51 |
50,000 |
1,925,537 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
2.01%
1.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):